Ventus Therapeutics Announces Nomination of VENT-04, a First-in-Class, Oral,...
Targeting caspase-4/5 has the potential to address a broad range of inflammatory conditions, including inflammatory bowel disease, hidradenitis suppurativa, severe asthma, and chronic obstructive...
View ArticleVentus Thérapeutique annonce le choix du VENT-04, première petite molécule...
L’inhibition des caspases 4 et 5 pourrait permettre de traiter une panoplie de troubles inflammatoires : maladies inflammatoires de l’intestin, hidradénite suppurée, asthme sévère et maladie...
View ArticleCaspase-4 and -5 Biology in the Pathogenesis of Inflammatory Bowel Disease.
Smith AP, Creagh EM. Front Pharmacol. The post Caspase-4 and -5 Biology in the Pathogenesis of Inflammatory Bowel Disease. appeared first on Ventus Therapeutics.
View ArticleMendelian randomization study for the roles of IL-18 and IL-1 receptor...
Mi J, Liu Z, Pei S, Wu X, Zhao N, Jiang L, Zhang Z, Bai X. Int Immunopharmacol. The post Mendelian randomization study for the roles of IL-18 and IL-1 receptor antagonist in the development of...
View ArticleInterleukin-18 as a drug repositioning opportunity for inflammatory bowel...
Mokry LE, Zhou S, Guo C, Scott RA, Devey L, Langenberg C, Wareham N, Waterworth D, Cardon L, Sanseau P, Davey Smith G, Richards JB. Sci Rep. 2019 Jun 28;9(1):9386. The post Interleukin-18 as a drug...
View ArticleDysregulated Microbiota-Driven Gasdermin D Activation Promotes Colitis...
Gao H, Cao M, Yao Y, Hu W, Sun H, Zhang Y, Zeng C, Tang J, Luan S, Chen P. Front Immunol. 2021 Oct 14;12:750841. The post Dysregulated Microbiota-Driven Gasdermin D Activation Promotes Colitis...
View ArticleMonoclonal Antibodies Against Mature Interleukin-18 Ameliorate Colitis and...
Mu J, Maeda K, Ohashi A, Urano T, Nariai Y, Kamino H, Nakamura M, Yamamura T, Sawada T, Ishikawa E, Murate K, Yamamoto K, Hirose T, Furukawa K, Fujishiro M, Kawashima H. Dig Dis Sci. 2024...
View ArticleInterleukin 18 is a potent proliferative factor for intestinal mucosal...
Kanai T, Watanabe M, Okazawa A, Nakamaru K, Okamoto M, Naganuma M, Ishii H, Ikeda M, Kurimoto M, Hibi T. Gastroenterology. 2000 Dec;119(6):1514-23. The post Interleukin 18 is a potent proliferative...
View ArticleEpithelial-derived gasdermin D mediates nonlytic IL-1β release during...
Bulek K, Zhao J, Liao Y, Rana N, Corridoni D, Antanaviciute A, Chen X, Wang H, Qian W, Miller-Little WA, Swaidani S, Tang F, Willard BB, McCrae K, Kang Z, Dubyak GR, Cominelli F, Simmons A, Pizarro...
View ArticleVentus Therapeutics Appoints Georgia McGaughey, Ph.D., as Chair of Newly...
Board consists of world-renowned computer-driven drug discovery experts to support Ventus’ physics-based and AI/ML-enabled ReSOLVE® platform WALTHAM, Mass. & MONTREAL — December 16, 2025 —...
View ArticleVentus Therapeutics to Present at Morgan Stanley 23rd Annual Global...
WALTHAM, Mass. & MONTREAL — September 4, 2025 — (BUSINESS WIRE) — Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological,...
View ArticleVentus Thérapeutique présentera à la 23e conférence annuelle Morgan Stanley...
WALTHAM, Mass. et MONTRÉAL – 4 septembre 2025 – (BUSINESS WIRE) – Ventus Thérapeutique, une société biopharmaceutique de stade clinique, en phase II du développement de deux programmes de petites...
View ArticleVentus Thérapeutique présentera les résultats de l’essai de phase I sur le...
Le VENT‑03 a été bien toléré dans tous les groupes de dose Son profil pharmacocinétique est compatible avec une administration une fois par jour; les résultats pharmacodynamiques indiquent que l’agent...
View ArticleVentus Therapeutics to Present Phase 1 Results for VENT-03, a First-in-Class...
VENT-03 was well tolerated across dose cohorts Pharmacokinetic profile supports once-daily dosing; pharmacodynamic results indicate robust target engagement Phase 2 trial evaluating VENT-03 in...
View ArticleVentus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor...
WALTHAM, Mass. & MONTREAL — April 29, 2025 — (BUSINESS WIRE) — Ventus Therapeutics, a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for...
View ArticleVentus Thérapeutique présentera à la conférence Bloom Burton & Co Healthcare...
WALTHAM, Mass. et MONTRÉAL – 29 avril 2025 – (BUSINESS WIRE) – Ventus Thérapeutique, une importante société biopharmaceutique de stade clinique, en phase II du développement de deux programmes de...
View ArticleVentus Thérapeutique annonce la publication d’un article dans la revue...
Des connaissances privilégiées sur le site actif de cGAS (cyclic GMP-AMP synthase) ont permis de structurer une optimisation rationnelle d’inhibiteurs de cGAS Le lancement d’un essai de phase II sur...
View ArticleVentus Therapeutics Announces Publication in Nature’s Communications...
Unique insight into the cyclic GMP-AMP synthase (cGAS) active site provided a framework for rational optimization of cGAS inhibitors Phase 2 trial with Ventus’ first-in-class cGAS inhibitor, VENT-03,...
View ArticleVentus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial...
In addition to assessing the safety and tolerability, pharmacokinetics, and pharmacodynamics of VENT-02, the trial will evaluate biomarkers to elucidate the role of inflammation in disease activity...
View ArticleVentus Thérapeutique annonce l’administration du VENT-02, un inhibiteur oral...
En plus d’évaluer l’innocuité, la tolérabilité, la pharmacocinétique et la pharmacodynamique du VENT‑02, les chercheurs analyseront des biomarqueurs en vue d’élucider le rôle de l’inflammation dans...
View Article
![[-100%] Commodity Intelligence – (Android Apps)](http://play-lh.googleusercontent.com/j67-qJvmnn4xnVlYVZ9ZhtZUJIgwjKekJGoKQT6D1KHcWGZxtQaFroummEvwV17na7tyh1pGbbeWCRdWtTKqeg=w950-h950)
